StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca FX sensitivity: SEK impact on Total Revenue by Quarter

FX sensitivity (+5% vs USD): SEK impact on Total Revenue ($M) ($M)

AstraZeneca FX sensitivity: SEK impact on Total Revenue: $9M in Q2 2026, down 200.0% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q2 2026
9
Period ended Jun 30, 2026
Change on a year earlier
-200.0%
-9 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| SEK | | Operating expense | | 9.81 | | 9.25 | | 6 | | 9.50 | | 3 | | 9 | (71)”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Currency Sensitivity Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFX sensitivity (+5% vs USD): SEK impact on Total Revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20269-200.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20269-200.0%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20259-200.0%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-9-200.0%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-9-200.0%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-9-200.0%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-9-200.0%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20249+28.6%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20249+28.6%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20249+28.6%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20239+28.6%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20237+16.7%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20237+16.7%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20237+16.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20227+16.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20226+20.0%Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca FX sensitivity: SEK impact on Total Revenue ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fx-sens-sek-rev

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.

See a number that looks wrong?